Using Cell Therapies for Cancer and Beyond


Jennifer Buell, PhD, president and chief operating officer of Agenus, discussed cell therapy for multiple myeloma and COVID-19 respiratory distress.

“We're going to expand on the acute respiratory distress program... secondary to COVID... no one spoke about respiratory distress before COVID, and now we're seeing the real damaging effects of it... We are working... in advancing [cell therapies] in patients with infectious disease and ARDS. These cells...can repair lung tissue and dampen those pro-inflammatory cytokines that have been so challenging in patients with COVID.”

MiNK Therapeutics (formerly AgenTus Therapeutics), a subsidiary of Agenus, is targeting multiple indications with its cell therapies. Their 3 leading clinical programs are in cancers, including hematologic malignancies and solid tumors, graft-versus-host disease, and acute respiratory distress syndrome (ARDS).

A phase 2 clinical trial (NCT04754100) is currently evaluating AgenT-797, an allogeneic unmodified invariant natural killer T cell therapy for the treatment of relapsed/refractory multiple myeloma. The first patient was dosed in April 2021. The trial is evaluating the safety, tolerability, and preliminary clinical activity of agenT-797, with safety, dose correlation to adverse events, and finding a recommended dose as primary outcomes. The same agent is also being investigated for the treatment of ARDS in COVID-19.

GeneTherapyLive spoke with Agenus’s president and chief operating officer, Jennifer Buell, PhD, to learn more about the company’s clinical programs. She also discussed future research and plans for the company.

Agenus doses first cancer patient with iNKT cell therapy. News release. Agenus. April 14, 2021. Accessed August 5, 2021.
Related Videos
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Jennifer Taylor-Cousar, MD, MSCS, on Early Signals of Efficacy With Cystic Fibrosis Gene Therapy
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi
Ignacio Mata, PhD, an associate professor of neurology at the Cleveland Clinic Lerner Institute
© 2024 MJH Life Sciences

All rights reserved.